- User Profile
- Watchlists
- Dividend at a Discount - 30 quality companies
Dividend at a Discount - 30 quality companies
30 quality businesses from the US, Europe, and Canada with yields above 1.5%, mispriced by the market, not by their fundamentals. Do your own research. This is not investment advice.
Watching
30
| Company | Price & Valuation | FV & Narrative | Valuation | Growth | Analyst Target | |
|---|---|---|---|---|---|---|
ASRNL ASR Nederland €72.40n/aintrinsic discount 4.2%7D 14.1%3M The author hasn't set a fair value for ASRNL | ||||||
DPZ Domino's Pizza US$350.00n/aintrinsic discount 2.4%7D 11.6%3M The author hasn't set a fair value for DPZ | ||||||
VZ Verizon Communications US$50.10n/aintrinsic discount 1.3%7D 5.0%3M The author hasn't set a fair value for VZ | ||||||
KMB Kimberly-Clark US$109.55n/aintrinsic discount 0.2%7D 11.8%3M The author hasn't set a fair value for KMB | ||||||
LMT Lockheed Martin US$563.85n/aintrinsic discount 0.05%7D 9.2%3M The author hasn't set a fair value for LMT | ||||||
RF Regions Financial US$30.33n/aintrinsic discount -0.3%7D 10.9%3M The author hasn't set a fair value for RF | ||||||
GILD Gilead Sciences US$145.68n/aintrinsic discount -0.3%7D 11.1%3M The author hasn't set a fair value for GILD | ||||||
ZTS Zoetis US$77.3416.8% undervalued intrinsic discount -0.5%7D -0.3%3M | ||||||
BMY Bristol-Myers Squibb US$66.58n/aintrinsic discount -0.6%7D 21.2%3M The author hasn't set a fair value for BMY | ||||||
BDX Becton Dickinson US$189.52n/aintrinsic discount -1.3%7D 30.4%3M The author hasn't set a fair value for BDX | ||||||
NOVO B Novo Nordisk DKK 295.50n/aintrinsic discount -1.8%7D 3.7%3M The author hasn't set a fair value for NOVO B | ||||||
BIP Brookfield Infrastructure Partners US$38.10n/aintrinsic discount -2.2%7D -2.0%3M The author hasn't set a fair value for BIP | ||||||
MDLZ Mondelez International US$62.36n/aintrinsic discount -3.2%7D 2.1%3M The author hasn't set a fair value for MDLZ | ||||||
BF.B Brown-Forman US$27.22n/aintrinsic discount -4.3%7D 8.2%3M The author hasn't set a fair value for BF.B |
Watching
30
| Company | Price & Valuation | FV & Narrative | Valuation | Growth | Analyst Target | |
|---|---|---|---|---|---|---|
ASRNL ASR Nederland 4.2%7D 14.1%3M | €72.40 n/aintrinsic discount | The author hasn't set a fair value for ASRNL | PE 12.8x | E 3.6% | €73.80 | |
SPGI S&P Global 2.7%7D 3.3%3M | US$442.89 n/aintrinsic discount | The author hasn't set a fair value for SPGI | PE 26.5x | E 6.6% | US$519.30 | |
DPZ Domino's Pizza 2.4%7D 11.6%3M | US$350.00 n/aintrinsic discount | The author hasn't set a fair value for DPZ | PE 19.4x | E 6.2% | US$380.29 | |
ACN Accenture 2.3%7D -3.6%3M | US$189.61 n/aintrinsic discount | The author hasn't set a fair value for ACN | PE 14.9x | E 8.3% | US$184.19 | |
VZ Verizon Communications 1.3%7D 5.0%3M | US$50.10 n/aintrinsic discount | The author hasn't set a fair value for VZ | PE 12.9x | E 9.4% | US$51.56 | |
CMCSA Comcast 0.8%7D 8.0%3M | US$27.06 n/aintrinsic discount | The author hasn't set a fair value for CMCSA | PE 8.6x | E 0.7% | US$30.08 | |
KHC Kraft Heinz 0.5%7D 8.8%3M | US$25.70 n/aintrinsic discount | The author hasn't set a fair value for KHC | PS 1.2x | E 65.0% | US$25.09 | |
KMB Kimberly-Clark 0.2%7D 11.8%3M | US$109.55 n/aintrinsic discount | The author hasn't set a fair value for KMB | PE 21.6x | E 16.4% | US$118.60 | |
LMT Lockheed Martin 0.05%7D 9.2%3M | US$563.85 n/aintrinsic discount | The author hasn't set a fair value for LMT | PE 20.7x | E 8.1% | US$632.95 | |
MKC McCormick -0.1%7D 18.8%3M | US$55.33 n/aintrinsic discount | The author hasn't set a fair value for MKC | PE 9.2x | E -24.8% | US$60.62 | |
RF Regions Financial -0.3%7D 10.9%3M | US$30.33 n/aintrinsic discount | The author hasn't set a fair value for RF | PE 12x | E 4.7% | US$32.94 | |
GILD Gilead Sciences -0.3%7D 11.1%3M | US$145.68 n/aintrinsic discount | The author hasn't set a fair value for GILD | PS 5.9x | E 45.4% | US$157.41 | |
PFE Pfizer -0.4%7D 9.1%3M | US$27.96 n/aintrinsic discount | The author hasn't set a fair value for PFE | PE 36.7x | E 8.0% | US$28.61 | |
ZTS Zoetis -0.5%7D -0.3%3M | US$77.34 16.8% undervalued intrinsic discount | PE 12.1x | E 3.5% | US$96.00 | ||
DGE Diageo -0.6%7D 14.7%3M | UK£17.09 n/aintrinsic discount | The author hasn't set a fair value for DGE | PE 29.6x | E 17.3% | UK£19.88 | |
BMY Bristol-Myers Squibb -0.6%7D 21.2%3M | US$66.58 n/aintrinsic discount | The author hasn't set a fair value for BMY | PE 14.7x | E -6.9% | US$66.21 | |
BX Blackstone -0.7%7D 21.8%3M | US$142.39 n/aintrinsic discount | The author hasn't set a fair value for BX | PE 32.4x | E 26.0% | US$144.05 | |
BDX Becton Dickinson -1.3%7D 30.4%3M | US$189.52 n/aintrinsic discount | The author hasn't set a fair value for BDX | PE 31.3x | E 27.6% | US$194.42 | |
WKL Wolters Kluwer -1.4%7D 9.7%3M | €70.22 n/aintrinsic discount | The author hasn't set a fair value for WKL | PE 11.7x | E 2.8% | €89.03 | |
CVX Chevron -1.7%7D 8.6%3M | US$201.86 n/aintrinsic discount | The author hasn't set a fair value for CVX | PE 19.2x | E 2.1% | US$218.29 | |
PEP PepsiCo -1.7%7D -0.3%3M | US$141.07 n/aintrinsic discount | The author hasn't set a fair value for PEP | PE 18.4x | E 5.1% | US$155.00 | |
NOVO B Novo Nordisk -1.8%7D 3.7%3M | DKK 295.50 n/aintrinsic discount | The author hasn't set a fair value for NOVO B | PE 11.2x | E 1.2% | DKK 309.73 | |
BIP Brookfield Infrastructure Partners -2.2%7D -2.0%3M | US$38.10 n/aintrinsic discount | The author hasn't set a fair value for BIP | PE 61x | E -115.3% | US$47.10 | |
MDT Medtronic -2.3%7D 23.3%3M | US$91.23 n/aintrinsic discount | The author hasn't set a fair value for MDT | PE 24.3x | E 10.1% | US$98.84 | |
INTU Intuit -2.4%7D 1.2%3M | US$358.06 n/aintrinsic discount | The author hasn't set a fair value for INTU | PE 21.5x | E 11.7% | US$420.33 | |
FAST Fastenal -2.9%7D 13.2%3M | US$49.78 n/aintrinsic discount | The author hasn't set a fair value for FAST | PE 42.2x | E 9.1% | US$48.53 | |
MDLZ Mondelez International -3.2%7D 2.1%3M | US$62.36 n/aintrinsic discount | The author hasn't set a fair value for MDLZ | PE 22.6x | E 8.0% | US$69.13 | |
ABBV AbbVie -3.6%7D 20.0%3M | US$255.48 n/aintrinsic discount | The author hasn't set a fair value for ABBV | PE 72x | E 23.4% | US$276.59 | |
CLX Clorox -3.9%7D 15.1%3M | US$102.53 n/aintrinsic discount | The author hasn't set a fair value for CLX | PE 21.1x | E 10.3% | US$101.65 | |
BF.B Brown-Forman -4.3%7D 8.2%3M | US$27.22 n/aintrinsic discount | The author hasn't set a fair value for BF.B | PE 17.5x | E 4.6% | US$28.08 |